This site is intended for healthcare professionals

Arcutis provides update on phase IIa clinical trial for ARQ 252 Cream as a treatment for vitiligo.

Read time: 1 mins
Last updated:2nd Jul 2021
Published:2nd Jul 2021
Arcutis Biotherapeutics, Inc. announced its decision to terminate the recently initiated Phase IIa clinical trial evaluating ARQ 252, a topical small molecule inhibitor of Janus kinase type 1 (JAK1), as a potential treatment for vitiligo (ARQ-252-213). Arcutis’ decision is based on further analyses of the ARQ 252 drug formulation used in both this vitiligo study and the recently completed Phase IIb study evaluating ARQ-252 for the treatment of chronic hand eczema (ARQ-252-205).
Condition: Vitiligo
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest